
Eli Lilly and Company’s EBGLYSS Shows Up to Four Years of Sustained Control in Atopic Dermatitis
Eli Lilly and Company Reports Up to Four Years of Sustained Disease Control with EBGLYSS (lebrikizumab-lbkz) in Moderate-to-Severe Atopic Dermatitis Eli Lilly and Company has unveiled compelling new long-term data demonstrating that its biologic therapy EBGLYSS (lebrikizumab-lbkz) can deliver sustained…












